**Background**

The French regional pneumococcal observatories (ORP) network was created in 1995, it participates to the close monitoring of the trends in antimicrobial resistance and serotype distribution with the National Reference Centre for Pneumococci (NRCP) and the INVS.

The ORP network includes:

- ORP Alsace, CH Mulhouse – graveta@ch-mulhouse.fr
- ORP Pays de Loire, CHU Angers
- ORP Auverge, ORP Limousin
- ORP Languedoc-Roussillon
- ORP Pays de Loire
- ORP Poitou-Charentes
- ORP Bretagne
- ORP Normandie
- ORP Champagne Ardenne
- ORP Midi-Pyrénées
- ORP Nord-Pas de Calais
- ORP Midi-Pyrénées
- ORP Brittany
- ORP Normandy
- ORP Champagne Ardenne
- ORP InVS

**Methods**

Antimicrobial susceptibility testing was performed on 5,194 isolates of *S. pneumoniae* recovered from cerebrospinal fluid (CSF), blood, middle ear fluid (MEF) and pleural fluid during the year 2009 by the 23 ORP. MICs of penicillin (P), amoxicillin (AMX) and cefotaxime (CTX) were determined by the agar dilution method and interpreted according to the Antibiotics Comity of the French Society of Microbiology breakpoints. Serotyping was performed at the NRCP with serotype-specific antisera, by latex agglutination test.

**Results**

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of strains</th>
<th>Blood (%)</th>
<th>CSF (%)</th>
<th>MEF (%)</th>
<th>A (%)</th>
<th>C (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>1022</td>
<td>45.5</td>
<td>44.1</td>
<td>6.8</td>
<td></td>
<td>62.5</td>
</tr>
<tr>
<td>2005</td>
<td>1833</td>
<td>33.7</td>
<td>38.0</td>
<td>63.3</td>
<td>54.3</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>1439</td>
<td>27.8</td>
<td>33.7</td>
<td>60.2</td>
<td>50.1</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>1497</td>
<td>23.7</td>
<td>29.2</td>
<td>63.0</td>
<td>48.3</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>3492</td>
<td>43.2</td>
<td>38.5</td>
<td>45.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>4503</td>
<td>38.7</td>
<td>38.0</td>
<td>40.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>3230</td>
<td>32.5</td>
<td>34.6</td>
<td>32.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>3658</td>
<td>27.2</td>
<td>26.1</td>
<td>26.8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion**

We observed a significant decrease of PDSP between 2003 and 2009 (50.2 to 33.0%). The decrease coincided with the introduction of PCV7 and with a general reduction in levels of antibiotic consumption in France. This ongoing survey is necessary to evaluate the changes in antibiotic susceptibility and serotypes distribution in France after PCV13 introduction (June 2010).

Acknowledges: Thanks to GSK, Pfizer and bioMérieux